|
|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2026
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/34430
| Title: | THE STRATEGIES OF SUBACUTE THYROIDITIS MANAGEMENT |
| Authors: | Tarchoun, Hamza |
| Keywords: | subacute thyroiditis;thyrotoxicosis;hypothyroidism;glucocorticosteroid;NSAIDs |
| Issue Date: | 2026 |
| Publisher: | Centrul Editorial-Poligrafic Medicina |
| Citation: | Tarchoun, Hamza. THE STRATEGIES OF SUBACUTE THYROIDITIS MANAGEMENT. In: MedEspera 2026, p. 615. ISBN 978-9975-82-486-6. |
| Abstract: | Introduction. Subacute thyroiditis, or De Quervain thyroiditis, or granulomatous thyroiditis, is the inflammation in the thyroid gland, characteristic by gland enlargement, pain and thyrotoxicosis, caused the most probably due to viral infection, mainly post upper respiratory tract infections. Subacute thyroiditis pass by three phases, first one is thyrotoxicosis recognized by high elevation of thyroid hormones T3 and T4, the second phase is hypothyroidal phase we find low level of T3 and T4, the last one is the recovery after management of the disease which is differ depend on severity. Aim of study. The aim of this study is to identify the different methods of treating the disease and their underlying principles, the doses of each treatment and the duration of using it. It also seeks to determine their effectiveness in various cases and comparison between the strategies of treatment. Methods and materials. A descriptive and analytical literature review was performed utilising major biomedical databases such as PubMed, Web of Science, and Google Scholar. Peer-reviewed papers, systematic reviews, and international guidelines published primarily between 2015 and 2025 were evaluated. Results. The aim from management of subacute thyroiditis is pain relief and control symptoms and to reach complete recovery without the development of delayed hypothyroidism. The management of SAT is based on two strategies according to the severity of the patient, if the patient in mild to moderate disease non -steroidal anti-inflammatory drugs are the choice, and if the case in moderate to severe disease the glucocorticosteroid drugs are the strategy of treatment we will follow. In the case of NSAIDs strategy, the drugs used mostly are salicylic acid with dose 600 mg orally every 6 hours or ibuprofen with dose 400 to 800 mg orally every 8 h. This strategy didn’t show high effectiveness especially with severe cases, so glucocorticosteroid can be the solution. We can start with a prednisolone initial dose of 40 mg daily for 1 -2 weeks and over 2-4 weeks we decrease the doses. GC strategy shows effectiveness better than NSAIDs especially in severe cases but there are some studies reporting that the recurrence of the disease can be related by GC treatment. With the anti-inflammatory drugs, in thyrotoxicosis phase beta blockers can be used to control this phase and in hypothyroidism phase hormones replacement can be a solution like levothyroxine with dose 25-100 mcg/day. Conclusions. Glucocorticosteroid strategy and non-steroidal anti-inflammatory strategy both are used in subacute thyroiditis management but GC way shows more effectiveness while NSAIDs are safer for patients, so in mild to moderate cases the NSAIDs are the choice and only in severe case we use GCs and with controlled doses also we should check the case for the recurrency possibility. |
| metadata.dc.relation.ispartof: | MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026 |
| URI: | https://medespera.md/documents/abstract-book-4.pdf https://repository.usmf.md/handle/20.500.12710/34430 |
| ISBN: | 978-9975-82-486-6 |
| Appears in Collections: | MedEspera 2026
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|